MA51208A - Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer - Google Patents
Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancerInfo
- Publication number
- MA51208A MA51208A MA051208A MA51208A MA51208A MA 51208 A MA51208 A MA 51208A MA 051208 A MA051208 A MA 051208A MA 51208 A MA51208 A MA 51208A MA 51208 A MA51208 A MA 51208A
- Authority
- MA
- Morocco
- Prior art keywords
- masked
- antibodies
- cancer treatment
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593712P | 2017-12-01 | 2017-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51208A true MA51208A (fr) | 2020-10-07 |
Family
ID=64665131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051208A MA51208A (fr) | 2017-12-01 | 2018-11-29 | Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11180552B2 (fr) |
| EP (1) | EP3717515A2 (fr) |
| JP (2) | JP7391845B2 (fr) |
| KR (1) | KR20200091901A (fr) |
| CN (1) | CN111448213A (fr) |
| AR (1) | AR113862A1 (fr) |
| AU (1) | AU2018375375A1 (fr) |
| BR (1) | BR112020009805A2 (fr) |
| CA (1) | CA3083946A1 (fr) |
| EA (1) | EA202091339A1 (fr) |
| IL (1) | IL274519A (fr) |
| MA (1) | MA51208A (fr) |
| MX (1) | MX2020005463A (fr) |
| SG (1) | SG11202004864TA (fr) |
| TW (1) | TWI831759B (fr) |
| WO (1) | WO2019108733A2 (fr) |
| ZA (1) | ZA202002923B (fr) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3551667A4 (fr) * | 2016-12-09 | 2020-06-17 | Seattle Genetics, Inc. | Anticorps bivalents masqués par des bobines enroulées |
| WO2020023702A1 (fr) * | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Nouveaux promédicaments d'il-21 et leurs procédés d'utilisation |
| TW202112801A (zh) * | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 純化遮蔽抗體之方法 |
| TW202112354A (zh) * | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 遮蔽抗體調配物 |
| EP3986935A4 (fr) | 2019-06-19 | 2023-08-30 | Lepu Biopharma Co., Ltd. | Anticorps anti-cd47 et leurs utilisations |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| WO2021173612A1 (fr) * | 2020-02-26 | 2021-09-02 | Sorrento Therapeutics, Inc. | Protéines de liaison à un antigène activables avec des fractions de masquage universelles |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| WO2021207657A1 (fr) * | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions contenant des anticorps activables |
| EP4168451A2 (fr) | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Agents de liaison à lair-1 et procédés d'utilisation associés |
| WO2022003568A1 (fr) | 2020-06-30 | 2022-01-06 | Dcprime B.V. | Utilisation de cellules dérivées de la leucémie dans des vaccins contre le cancer de l'ovaire |
| WO2022007947A1 (fr) * | 2020-07-10 | 2022-01-13 | 信达生物制药(苏州)有限公司 | Combinaison d'anticorps anti-cd47 ou de fragment de liaison à l'antigène de celui-ci et d'inhibiteur d'adn méthyltransférase et son utilisation |
| CN120040592A (zh) * | 2020-07-31 | 2025-05-27 | 百奥泰生物制药股份有限公司 | Cd47抗体及其应用 |
| WO2022057939A1 (fr) * | 2020-09-21 | 2022-03-24 | I-Mab Biopharma Co., Ltd. | Composition pharmaceutique comprenant un anticorps cd47 et un inhibiteur de pd-1/pd-l1 |
| WO2022081794A1 (fr) * | 2020-10-15 | 2022-04-21 | Tavotek Biotherapeutics (Hong Kong) Limited | Produits biologiques protégés à domaines de masquage pour protéger la capacité de liaison à l'antigène de produits biologiques et utilisations associées |
| CN117062835A (zh) * | 2021-01-20 | 2023-11-14 | 昂科里斯庞斯公司 | 免疫调节性抗体及其用途 |
| BR112023016713A2 (pt) * | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo |
| WO2022190058A1 (fr) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Méthodes de vaccination et utilisation d'un blocage de cd47 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
| EP4359413A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| US20240165229A1 (en) | 2021-06-29 | 2024-05-23 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
| US20240352080A1 (en) * | 2021-07-14 | 2024-10-24 | Seagen Inc. | Antibody Masking Domains |
| CN115925940B (zh) * | 2021-08-24 | 2026-02-27 | 上海鑫湾生物科技有限公司 | 特异性结合cd47的抗体、其重组溶瘤病毒及其用途 |
| AR127270A1 (es) * | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | Formulación de anticuerpos anti-cd47 |
| WO2023070353A1 (fr) * | 2021-10-27 | 2023-05-04 | Adagene Pte. Ltd. | Anticorps anti-cd47 et leurs procédés d'utilisation |
| EP4423078A1 (fr) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Dérivés de pyridine-3(2h)-one |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4458862A4 (fr) * | 2021-12-27 | 2026-05-06 | Shanghai Sinobay Biotechnology Co Ltd | Activateur de lymphocytes t bispécifique, virus oncolytique recombinant de celui-ci et utilisation associée |
| CA3248911A1 (fr) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Inhibiteurs de poly(adénosine diphosphate-ribose) polymérase 7 |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| EP4511127A1 (fr) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Composés modulateurs de kras g12d |
| WO2024006929A1 (fr) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Composés cd73 |
| CA3259040A1 (fr) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (fr) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| WO2024215754A1 (fr) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Composés modulateurs de kras |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | Kras調節化合物 |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| KR20260056204A (ko) * | 2023-08-14 | 2026-04-24 | 보로 테라퓨틱스, 인코포레이티드 | 표적 세포에 대한 골수 세포 활성을 조건부로 촉진시키는 치료용 결합제 및 이의 용도 |
| EP4774280A1 (fr) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Composés de modulation de kras g12d |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (fr) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN118005795B (zh) * | 2024-04-09 | 2024-06-28 | 天津旷博同生生物技术有限公司 | 一种抗人cd64抗体及应用 |
| WO2025245003A1 (fr) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026136515A1 (fr) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Inhibiteurs de parp7 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5057604A (en) | 1988-08-03 | 1991-10-15 | Washington University | Novel monoclonal antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| EP0590058B1 (fr) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | ANTICORP HUMANISE specifique pour heregulin |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| WO1993010260A1 (fr) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Utilisation de la neuraminidase extracellulaire pour lutter contre la degradation d'oligosaccharides de la glycoproteine |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| EP0871490B1 (fr) | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Segments de liaison hydrazone ramifies |
| CA2303072A1 (fr) | 1997-09-11 | 1999-03-18 | Chugai Seiyaku Kabushiki Kaisha | Anticorps monoclonal induisant l'apoptose |
| CA2226962A1 (fr) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Utilisation d'agents liants a cd47 et ces ligands pour le traitement ou prophylaxie de maladies inflammatoire, autoimmunitaire et allergique et pour le traitement de rejet de greffons |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| US8613922B2 (en) | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Cd47部分ペプチドと抗shps−1モノクロナール抗体 |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| JP4637749B2 (ja) | 2003-11-11 | 2011-02-23 | 中外製薬株式会社 | ヒト化抗cd47抗体 |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| WO2007008848A2 (fr) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Composes de monomethylvaline presentant des modifications carboxy phenylalanine a la terminaison c |
| US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| EP2190861A4 (fr) | 2007-08-22 | 2011-03-30 | Univ California | Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci |
| JP2011500005A (ja) | 2007-10-11 | 2011-01-06 | ユニバーシティー ヘルス ネットワーク | ヒト造血幹細胞の生着を増加させるためのSIRPα−CD47相互作用の調節およびそのための化合物 |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| KR100936277B1 (ko) | 2007-11-20 | 2010-01-13 | 한국과학기술연구원 | 스핑고모나스 속 박테리아 균주와 아스페질러스 속 곰팡이균주의 혼합배양방법, 이로부터 유래한 신규항암-항생물질인 글리오니트린, 및 상기 글리오니트린 또는이의 약학적으로 허용가능한 염을 유효성분으로 하는약학적 조성물 |
| CA2711370C (fr) | 2008-01-15 | 2017-06-13 | The Board Of Trustees Of The Leland Stanford Junior University | Marqueurs des cellules souches de la leucemie myeloide aigue |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| EP2111869A1 (fr) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions et procédés pour renforcer le système immunitaire |
| PL2282773T3 (pl) | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej |
| WO2010017332A2 (fr) | 2008-08-07 | 2010-02-11 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Radioprotecteurs ciblant la thrombospondine-1 et cd47 |
| US8895702B2 (en) * | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| EP3543256A1 (fr) * | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Compositions d anticorps modifiées et leurs procédés de production et d'utilisation |
| CN102712696A (zh) | 2009-09-16 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
| US20110206696A1 (en) | 2010-01-25 | 2011-08-25 | The Washington University | Methods for inhibiting bone loss and bone metastasis |
| AU2011252851B2 (en) | 2010-05-14 | 2016-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to CD47 |
| WO2012088309A1 (fr) | 2010-12-21 | 2012-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Procédés thérapeutiques et diagnostiques de manipulation de la phagocytose par la calréticuline et le récepteur apparenté à la lipoprotéine de faible densité. |
| EP3766511A1 (fr) * | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | Réactifs sirp-alpha de haute affinité |
| ME03512B (fr) | 2012-02-06 | 2020-04-20 | Inhibrx Inc | Anticorps anti-cd47 et leurs méthodes d'utilisation |
| US9487590B2 (en) * | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| RU2693078C2 (ru) | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| MX2015007446A (es) | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| JP6605957B2 (ja) | 2013-01-04 | 2019-11-13 | シトムクス セラピューティクス,インコーポレイティド | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| EP3311824B1 (fr) | 2013-02-05 | 2020-03-25 | The Board of Trustees of the Leland Stanford Junior University | Thérapies ciblées sur cd47 pour le traitement d'une maladie infectieuse |
| CA2905418C (fr) | 2013-03-13 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Procedes de modulation de la cytotoxicite chimiotherapeutique |
| CN105189556A (zh) | 2013-03-15 | 2015-12-23 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| US9945870B2 (en) | 2013-05-17 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| SG11201509595PA (en) | 2013-05-28 | 2015-12-30 | Dcb Usa Llc | Antibody locker for the inactivation of protein drug |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| WO2015086727A2 (fr) | 2013-12-11 | 2015-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nouveau procédé de pronostic pour patients atteints d'un cancer |
| CN105611944A (zh) | 2013-12-20 | 2016-05-25 | 豪夫迈·罗氏有限公司 | 抗ang2抗体和cd40激动剂的组合疗法 |
| US11046763B2 (en) | 2014-01-08 | 2021-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
| AU2015329696A1 (en) | 2014-10-10 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to eliminate cancer stem cells by targeting CD47 |
| WO2016065329A1 (fr) | 2014-10-24 | 2016-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions et procédés pour induire la phagocytose de cellules positives de classe i du cmh et pour contrer la résistance aux agents anti-cd47/sirpa |
| BR112017008959A2 (pt) | 2014-10-29 | 2018-01-16 | Seattle Genetics, Inc. | método para tratamento de uma doença. |
| WO2016081423A1 (fr) | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Anticorps anti-cd47, procédés et utilisations |
| HK1245154A1 (zh) | 2014-12-30 | 2018-08-24 | 细胞基因公司 | 抗cd47抗体及其用途 |
| AR103868A1 (es) | 2015-03-04 | 2017-06-07 | Sorrento Therapeutics Inc | Anticuerpos anti-cd47 como agentes terapéuticos |
| AU2016258988A1 (en) * | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
| WO2017012771A1 (fr) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Sels d'addition d'acide sulfonique de filgotinib cristallin |
| TWI572317B (zh) | 2015-08-05 | 2017-03-01 | 梓源生技有限公司 | 體內固定裝置 |
| US20170071918A1 (en) | 2015-09-16 | 2017-03-16 | The University Of Hong Kong | Combination Use of CD47 Antibodies/Inhibitors with Sorafenib for Treatment of Liver Cancer |
| CN116425875A (zh) | 2015-09-18 | 2023-07-14 | 安驰肿瘤公司 | 治疗性cd47抗体 |
| US9650441B2 (en) | 2015-09-21 | 2017-05-16 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
| KR102988978B1 (ko) | 2015-12-11 | 2026-07-10 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Cd47 및 egfr의 이중 표적화를 이용한 암의 치료 |
| CA3011097C (fr) | 2016-01-11 | 2022-12-20 | Forty Seven, Inc. | Anticorps monoclonaux anti-cd47 humanises, de souris ou chimeriques |
| AU2017210224B2 (en) | 2016-01-21 | 2024-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
| WO2017196793A1 (fr) | 2016-05-09 | 2017-11-16 | Celgene Corporation | Anticorps cd47 et leurs méthodes d'utilisation |
| EP3458094A4 (fr) | 2016-05-19 | 2020-01-08 | Adaerata, Limited Partnership | Méthodes de prévention ou de traitement de cancers positifs pour slamf7 et négatifs pour slamf7 |
| CN106084052B (zh) | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
| JP7241677B2 (ja) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗cd47併用療法 |
| US20200140565A1 (en) | 2016-10-20 | 2020-05-07 | I-Mab | Novel cd47 monoclonal antibodies and uses thereof |
| EP3538557A4 (fr) | 2016-11-08 | 2020-11-18 | Ablexis, LLC | Anticorps anti-cd47 |
| TW201819413A (zh) | 2016-11-28 | 2018-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Cd47抗體、其抗原結合片段及其醫藥用途 |
| EP3551667A4 (fr) | 2016-12-09 | 2020-06-17 | Seattle Genetics, Inc. | Anticorps bivalents masqués par des bobines enroulées |
| EP3345924A1 (fr) | 2017-01-10 | 2018-07-11 | Universität Duisburg-Essen | Emploi d'anticorps cd47 |
| KR102607101B1 (ko) | 2017-01-26 | 2023-11-29 | 제트엘아이피 홀딩 리미티드 | Cd47 항원 결합 유닛 및 그것의 사용 |
| MX2020001309A (es) | 2017-08-02 | 2020-08-20 | Phanes Therapeutics Inc | Anticuerpos anti-cd47 y sus usos. |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| CN108503708B (zh) | 2017-09-01 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd47抗体及其用途 |
-
2018
- 2018-11-29 AR ARP180103511A patent/AR113862A1/es not_active Application Discontinuation
- 2018-11-29 AU AU2018375375A patent/AU2018375375A1/en not_active Abandoned
- 2018-11-29 KR KR1020207018697A patent/KR20200091901A/ko not_active Withdrawn
- 2018-11-29 SG SG11202004864TA patent/SG11202004864TA/en unknown
- 2018-11-29 MX MX2020005463A patent/MX2020005463A/es unknown
- 2018-11-29 BR BR112020009805-1A patent/BR112020009805A2/pt not_active IP Right Cessation
- 2018-11-29 EP EP18819299.1A patent/EP3717515A2/fr not_active Withdrawn
- 2018-11-29 CA CA3083946A patent/CA3083946A1/fr active Pending
- 2018-11-29 WO PCT/US2018/062961 patent/WO2019108733A2/fr not_active Ceased
- 2018-11-29 US US16/203,809 patent/US11180552B2/en active Active
- 2018-11-29 TW TW107142777A patent/TWI831759B/zh not_active IP Right Cessation
- 2018-11-29 CN CN201880077186.7A patent/CN111448213A/zh active Pending
- 2018-11-29 JP JP2020529364A patent/JP7391845B2/ja active Active
- 2018-11-29 EA EA202091339A patent/EA202091339A1/ru unknown
- 2018-11-29 MA MA051208A patent/MA51208A/fr unknown
-
2020
- 2020-05-07 IL IL274519A patent/IL274519A/en unknown
- 2020-05-19 ZA ZA2020/02923A patent/ZA202002923B/en unknown
-
2021
- 2021-10-20 US US17/505,911 patent/US12071480B2/en active Active
-
2023
- 2023-11-22 JP JP2023198049A patent/JP2024026144A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020005463A (es) | 2020-09-07 |
| TW201925227A (zh) | 2019-07-01 |
| TWI831759B (zh) | 2024-02-11 |
| US11180552B2 (en) | 2021-11-23 |
| AU2018375375A1 (en) | 2020-05-28 |
| IL274519A (en) | 2020-06-30 |
| KR20200091901A (ko) | 2020-07-31 |
| US12071480B2 (en) | 2024-08-27 |
| BR112020009805A2 (pt) | 2020-10-13 |
| US20220135674A1 (en) | 2022-05-05 |
| WO2019108733A3 (fr) | 2019-08-15 |
| CA3083946A1 (fr) | 2019-06-06 |
| EA202091339A1 (ru) | 2020-10-21 |
| JP7391845B2 (ja) | 2023-12-05 |
| JP2024026144A (ja) | 2024-02-28 |
| SG11202004864TA (en) | 2020-06-29 |
| JP2021503927A (ja) | 2021-02-15 |
| EP3717515A2 (fr) | 2020-10-07 |
| WO2019108733A2 (fr) | 2019-06-06 |
| US20190185561A1 (en) | 2019-06-20 |
| AR113862A1 (es) | 2020-06-17 |
| CN111448213A (zh) | 2020-07-24 |
| ZA202002923B (en) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1023I2 (fr) | Anticorps thérapeutiques et leurs utilisations | |
| MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
| EP3625263A4 (fr) | Anticorps anti-galectine-9 et leurs utilisations | |
| EP3621642A4 (fr) | Anticorps monoclonaux humains contre lag3 et leurs utilisations | |
| EP3383916A4 (fr) | Anticorps anti-cd73 et leurs utilisations | |
| EP3759143A4 (fr) | Anticorps anti-tigit et leurs utilisations | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| EP3389702A4 (fr) | Anticorps anti-lag-3 et leurs utilisations | |
| EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
| MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
| SG11202004864TA (en) | Cd47 antibodies and uses thereof for treating cancer | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| EP3377102A4 (fr) | Anticorps anti-pd-1 et leurs utilisations thérapeutiques | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| EP3426686A4 (fr) | Anticorps anti-pacap humanisés et leurs utilisations | |
| EP3328895A4 (fr) | Anticorps anti-pd-l1 et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
| EP3283517A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3383904A4 (fr) | Anticorps ctla-4 et leurs utilisations | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| EP3661555A4 (fr) | Anticorps bispécifiques et leurs utilisations | |
| EP3790586A4 (fr) | Anticorps anti-dll3 et leurs utilisations |